Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. tumor characteristic
Show results for
Products
Services
Applications
News
Articles
Downloads

Refine by
Date

  • Older

Tumor Characteristic Articles & Analysis

4 news found

The largest breast AI study to date shows value of Transpara in mammographic screening

The largest breast AI study to date shows value of Transpara in mammographic screening

The Cancer Registry of Norway is one of the oldest and most respected organisations of its kind in the world. It collects data and produces statistics of the cancer prevalence in Norway, has the administrative responsibility for the public screening programme in Norway and has an extensive research activity. In a recent study, the Registry used over 120,000 screening examinations from a ...

ByScreenPoint Medical


BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium

BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium

“We are excited about the broad potential of BXCL701 to extend the activity of checkpoint therapy into cold tumor settings and look forward to initiating the randomized trial extension in patients with adenocarcinoma and continuing patient enrollment in ...

ByBioXcel Therapeutics, Inc.


NIH grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403

NIH grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403

CTT1403, with its longer circulating time and better tumor targeting characteristics, offers distinct advantages in this treatment arena providing the patient with cost and treatment benefits,” commented Dr. ...

ByCancer Targeted Technology


ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

Secondary endpoints included anti-tumor effects and cellular immune response, plus overall survival. To identify immunological and molecular signatures of responses, three serial liver biopsies (before, during, and after virotherapy) allowed for in-depth analyses of pathological tumor characteristics, tumor-infiltrating immune ...

ByORYX GmbH & Co. KG

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT